Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 42

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 42
---
 to raise additional funds to complete such short-term operations. Such additional fundraises may not be available
or available on terms acceptable to us.

| 22 |

If you purchase our securities in either the Company Offering or the Inducement Offering you may incur immediate and substantial dilution in the book value of your shares.

The combined public offering price
per share of our common stock and accompanying warrant may be substantially higher than the net tangible book value per share of our common
stock immediately prior to the offering. After giving effect to the assumed sale of shares of our common stock and accompanying warrants
in this Company Offering, at an assumed combined public offering price of $ per
share and accompanying warrant (the last reported sale price of our common stock on The Nasdaq Capital Market on August ,
2025), and after deducting the placement agent fees and estimated offering expenses payable by us and attributing no value to the warrants
sold in this offering, purchasers of our common stock in this offering will incur immediate dilution of $ per
share in the net tangible book value of the common stock they acquire. In the event that you exercise your warrants, you may experience
additional dilution to the extent that the exercise price of the warrants is higher than the tangible book value per share of our common
stock. For a further description of the dilution that investors in this offering may experience, see “Dilution.”

In addition, to the extent that
outstanding stock options or warrants, including the Inducement Warrants have been or may be exercised, outstanding restricted stock units
have been or may be settled or other shares are issued, you may experience further dilution.

We have broad discretion in the use of the net proceeds we receive from the Company Offering and may not use them effectively.

Our management will have broad
discretion in the application of the net proceeds we receive in the Company Offering, including for any of the purposes described in the
section entitled “Use of Proceeds,” and you will not have the opportunity as part of your investment
decision to assess whether our management is using the net proceeds appropriately. Because of the number and variability of factors that
will determine our use of our net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse
effect on our business and cause the price of our common stock to decline.

Future sales of substantial amounts of our common stock could adversely affect the